Tenvir AF (Tenofovir alafenamide)

Tenvir AF (Tenofovir alafenamide) 

Tenofovir Alafenamide: Uses, Advantages, Dosage, and Safety Overview

Tenofovir alafenamide (TAF) is an antiviral medication widely used in the treatment and prevention of chronic viral infections, particularly HIV-1 and chronic hepatitis B (HBV). It is a prodrug of tenofovir, meaning it converts into the active form inside the body. Compared with its earlier version, tenofovir disoproxil fumarate (TDF), TAF delivers higher concentrations of the active drug into infected cells while keeping overall blood exposure lower. This results in similar antiviral effectiveness with improved kidney and bone safety.

Indications

Tenofovir alafenamide is prescribed for:

• HIV-1 infection, as part of combination antiretroviral therapy.

• Chronic hepatitis B (HBV) in adults and adolescents with active disease.

• HIV pre-exposure prophylaxis (PrEP) in selected individuals (TAF/FTC combinations), excluding those with receptive vaginal sex due to limited study data.

Mechanism of Action

After being absorbed and processed in the body, TAF converts to tenofovir diphosphate — a nucleotide reverse transcriptase inhibitor (NRTI). This compound blocks the viral reverse transcriptase enzyme, preventing viruses from copying their genetic material and producing new viral particles.

Dosage (General Overview)

TAF is taken once daily, usually as part of a fixed-dose combination tablet.
Common regimens include:

• 25 mg daily for hepatitis B monotherapy.

• 10 mg or 25 mg daily when used in HIV combination therapy (dose depends on accompanying drugs).

• 25 mg TAF + 200 mg FTC once daily for approved PrEP combinations.

Dosing must always follow a healthcare provider’s instructions.

Side Effects and Precautions

TAF is generally well tolerated. Common side effects include headache, nausea, fatigue, and mild gastrointestinal discomfort. It has a more favorable profile for kidney function and bone mineral density compared to older formulations. However, individuals with advanced liver disease, hepatitis flare risk, or HIV/HBV co-infection require careful monitoring. Sudden discontinuation may worsen hepatitis B.

Conclusion

Tenofovir alafenamide represents a major improvement in antiviral therapy, offering strong viral suppression with enhanced long-term safety. Its once-daily dosing and reduced toxicity make it an important option for both HIV and HBV management.